CN101851170B - 一种氯桂丁胺ⅱ型晶体 - Google Patents
一种氯桂丁胺ⅱ型晶体 Download PDFInfo
- Publication number
- CN101851170B CN101851170B CN 201010179540 CN201010179540A CN101851170B CN 101851170 B CN101851170 B CN 101851170B CN 201010179540 CN201010179540 CN 201010179540 CN 201010179540 A CN201010179540 A CN 201010179540A CN 101851170 B CN101851170 B CN 101851170B
- Authority
- CN
- China
- Prior art keywords
- chlocibutamine
- dichlorophenyl
- preparation
- liters
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000013078 crystal Substances 0.000 title abstract description 18
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 10
- 238000006243 chemical reaction Methods 0.000 claims description 54
- 238000002360 preparation method Methods 0.000 claims description 46
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 39
- RRLUFPHCTSFKNR-UHFFFAOYSA-N 3-(3,4-dichlorophenyl)prop-2-enoic acid Chemical compound OC(=O)C=CC1=CC=C(Cl)C(Cl)=C1 RRLUFPHCTSFKNR-UHFFFAOYSA-N 0.000 claims description 37
- 239000012043 crude product Substances 0.000 claims description 31
- BHRZNVHARXXAHW-UHFFFAOYSA-N sec-butylamine Chemical compound CCC(C)N BHRZNVHARXXAHW-UHFFFAOYSA-N 0.000 claims description 30
- ZQGLIXRJEHNGSK-UHFFFAOYSA-N C=CC(OC(C=C1)=CC(Cl)=C1Cl)=O.Cl Chemical compound C=CC(OC(C=C1)=CC(Cl)=C1Cl)=O.Cl ZQGLIXRJEHNGSK-UHFFFAOYSA-N 0.000 claims description 28
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 27
- 238000002425 crystallisation Methods 0.000 claims description 26
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims description 26
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 14
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 235000011056 potassium acetate Nutrition 0.000 claims description 13
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 13
- 238000002835 absorbance Methods 0.000 claims description 9
- 238000002329 infrared spectrum Methods 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 13
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 238000001228 spectrum Methods 0.000 abstract description 2
- 238000003756 stirring Methods 0.000 description 46
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 43
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 42
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 29
- 230000008025 crystallization Effects 0.000 description 25
- 239000007788 liquid Substances 0.000 description 23
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 238000001914 filtration Methods 0.000 description 21
- 239000007789 gas Substances 0.000 description 21
- 238000007603 infrared drying Methods 0.000 description 20
- 238000005406 washing Methods 0.000 description 20
- 239000000243 solution Substances 0.000 description 15
- 230000003292 diminished effect Effects 0.000 description 14
- 239000000706 filtrate Substances 0.000 description 14
- 238000010992 reflux Methods 0.000 description 14
- 239000011345 viscous material Substances 0.000 description 14
- 239000003921 oil Substances 0.000 description 13
- ZWUSBSHBFFPRNE-UHFFFAOYSA-N 3,4-dichlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1Cl ZWUSBSHBFFPRNE-UHFFFAOYSA-N 0.000 description 12
- 238000010438 heat treatment Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 8
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 8
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 8
- 206010015037 epilepsy Diseases 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 238000005352 clarification Methods 0.000 description 7
- 230000006837 decompression Effects 0.000 description 7
- 238000000151 deposition Methods 0.000 description 7
- 230000008021 deposition Effects 0.000 description 7
- 238000004090 dissolution Methods 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 7
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 7
- 239000005457 ice water Substances 0.000 description 7
- 239000006210 lotion Substances 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- MRAPOOFJIGGHTI-UHFFFAOYSA-N Cl.C(C)(CC)N.CC(=O)C Chemical compound Cl.C(C)(CC)N.CC(=O)C MRAPOOFJIGGHTI-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- WXIUBYCJAAEOFL-UHFFFAOYSA-N [S].ClOCl Chemical class [S].ClOCl WXIUBYCJAAEOFL-UHFFFAOYSA-N 0.000 description 6
- 239000012295 chemical reaction liquid Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000001037 epileptic effect Effects 0.000 description 6
- 238000009413 insulation Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 229910000474 mercury oxide Inorganic materials 0.000 description 6
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical class [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 description 6
- 230000000630 rising effect Effects 0.000 description 6
- 229910001220 stainless steel Inorganic materials 0.000 description 6
- 239000010935 stainless steel Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 229960002790 phenytoin sodium Drugs 0.000 description 5
- FJPYVLNWWICYDW-UHFFFAOYSA-M sodium;5,5-diphenylimidazolidin-1-ide-2,4-dione Chemical compound [Na+].O=C1[N-]C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 FJPYVLNWWICYDW-UHFFFAOYSA-M 0.000 description 5
- -1 Carbamzepine Chemical compound 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 4
- 239000001961 anticonvulsive agent Substances 0.000 description 4
- 230000036461 convulsion Effects 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 3
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- APEJMQOBVMLION-UHFFFAOYSA-N cinnamamide Chemical compound NC(=O)C=CC1=CC=CC=C1 APEJMQOBVMLION-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229960001848 lamotrigine Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 description 2
- 229960001816 oxcarbazepine Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229940084026 sodium valproate Drugs 0.000 description 2
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- MHWXTWUFERXENO-UHFFFAOYSA-N C(C)(CC)N.CC(=O)C Chemical compound C(C)(CC)N.CC(=O)C MHWXTWUFERXENO-UHFFFAOYSA-N 0.000 description 1
- LAYCYGGHWOIGEJ-VMPITWQZSA-N C/C(/C(O)=O)=C\c1ccc(C)c(Cl)c1 Chemical compound C/C(/C(O)=O)=C\c1ccc(C)c(Cl)c1 LAYCYGGHWOIGEJ-VMPITWQZSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 150000003926 acrylamides Chemical class 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019628 coolness Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960002767 ethosuximide Drugs 0.000 description 1
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 229940072170 lamictal Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229940071462 oralone Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 description 1
- 229960002393 primidone Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 239000011122 softwood Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- PBJUNZJWGZTSKL-MRXNPFEDSA-N tiagabine Chemical compound C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C PBJUNZJWGZTSKL-MRXNPFEDSA-N 0.000 description 1
- 229960001918 tiagabine Drugs 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 description 1
- 229960005318 vigabatrin Drugs 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
- UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 description 1
- 229960002911 zonisamide Drugs 0.000 description 1
Images
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Abstract
Description
药物 | 剂量(mg/kg) | 动物数(只) | 给药前惊厥数(只) | 给药后惊厥率(%) |
2%吐温-80 | 等容积 | 20 | 20 | 20 |
氯桂丁胺 | 31.3 | 20 | 20 | 17 |
氯桂丁胺 | 50.0 | 20 | 20 | 11 |
氯桂丁胺 | 80.0 | 20 | 20 | 8 |
氯桂丁胺 | 128.0 | 20 | 20 | 0 |
苯妥英钠 | 24.6 | 20 | 20 | 0 |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010179540 CN101851170B (zh) | 2010-05-24 | 2010-05-24 | 一种氯桂丁胺ⅱ型晶体 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010179540 CN101851170B (zh) | 2010-05-24 | 2010-05-24 | 一种氯桂丁胺ⅱ型晶体 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101851170A CN101851170A (zh) | 2010-10-06 |
CN101851170B true CN101851170B (zh) | 2013-04-03 |
Family
ID=42802884
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201010179540 Expired - Fee Related CN101851170B (zh) | 2010-05-24 | 2010-05-24 | 一种氯桂丁胺ⅱ型晶体 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101851170B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101991561B (zh) * | 2010-11-11 | 2012-12-05 | 迪沙药业集团有限公司 | 氯桂丁胺组合物 |
CN102258508A (zh) * | 2011-04-14 | 2011-11-30 | 威海迪素制药有限公司 | 芳基丙烯酸衍生物抗癫痫的用途 |
CN103450042A (zh) * | 2012-05-30 | 2013-12-18 | 迪沙药业集团有限公司 | 一种氯桂丁胺化合物及其药学上可接受的盐 |
CN103922958B (zh) * | 2013-01-13 | 2017-08-11 | 威海迪素制药有限公司 | 一种氯桂丁胺iii型晶体 |
CN104030941B (zh) * | 2014-06-23 | 2016-04-27 | 常州大学 | 一种3-(4-羟基苯基)丙酰胺的合成方法 |
-
2010
- 2010-05-24 CN CN 201010179540 patent/CN101851170B/zh not_active Expired - Fee Related
Non-Patent Citations (3)
Title |
---|
Qiang Li et al..Pharmacokinetics of ,4–dichlorophenyl–propenoyl-sec. –butylamine (7903) in rats.《Asian Journal of Drug Metabolism and Pharmacokinetics》.2004,第4卷(第3期),205-208. |
Qiang Li et al..Pharmacokinetics of,4–dichlorophenyl–propenoyl-sec. –butylamine (7903) in rats.《Asian Journal of Drug Metabolism and Pharmacokinetics》.2004,第4卷(第3期),205-208. * |
李树新等.3,4-二氯苯丙稀酰另丁胺抗抑郁作用的药理研究.《中国药理学通报》.1991,第7卷(第4期),279-282. * |
Also Published As
Publication number | Publication date |
---|---|
CN101851170A (zh) | 2010-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101851170B (zh) | 一种氯桂丁胺ⅱ型晶体 | |
CN102249975B (zh) | (s)-4-羟基-2-氧代-1-吡咯烷乙酰胺晶型ⅰ及其制备方法和用途 | |
DK2216038T3 (en) | Pharmaceutical compositions for the treatment of anxiety and depression | |
CN101716214B (zh) | 含有蒲公英提取物的药物组合物及其制药用途和制备方法 | |
CN101838217B (zh) | 一种氯桂丁胺ⅰ型晶体 | |
CN106166150A (zh) | 右旋奥拉西坦在制药领域中的应用 | |
CN102140079B (zh) | 新乌碱及其制备方法和以该化合物为活性成分的药物组合物及用途 | |
CN1173134A (zh) | 乳香用于治疗阿尔茨海默症的用途 | |
CN104274692B (zh) | 金佛安神酒及其制备工艺 | |
CN102153614B (zh) | 止泻木总生物碱提取物的有效单体制备方法及其用途 | |
CN101816766A (zh) | 一种用于治疗抑郁症的中药组合物 | |
CN101991561B (zh) | 氯桂丁胺组合物 | |
CN1166669C (zh) | 斑蝥酸钠的制备工艺 | |
CN102603818B (zh) | 一种脑苷脂类化合物的制备方法及用途 | |
CN108640962B (zh) | 化合物三七皂苷st-4的制备方法及应用 | |
CN106265571A (zh) | 一种奥氮平片剂的制备方法 | |
CN106236760B (zh) | 人参皂苷c‑k与丙戊酸或丙戊酸的盐的组合物在制备抗癫痫药物中的应用 | |
CN103664905A (zh) | 盐酸坦度螺酮晶型ii及其制备方法 | |
CN103040869B (zh) | 一种人工熊胆粉及其制备方法 | |
CN103416746B (zh) | 一种降脂富硒茶色素及生产方法 | |
CN105963311A (zh) | 人参皂苷c-k与拉莫三嗪的组合物在制备抗癫痫药物中的应用 | |
CN110025758A (zh) | 一种醒脑静口服凝胶制剂及其制备方法 | |
CN104435298A (zh) | 一种抗抑郁药物组合物 | |
CN106061504A (zh) | 包括代谢型谷氨酸能受体亚型2的正别构调节物或正位激动剂的组合及其用途 | |
CN101519418A (zh) | 去氧胆酸镁盐的水合物的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: WEIHAI DISU PHARMACEUTICAL CO., LTD. DISHA PHARMAC Free format text: FORMER OWNER: WEIHAI DISU PHARMACEUTICAL CO., LTD. |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20110620 Address after: 264205 No. 1 South Qingdao Road, Weihai economic and Technological Development Zone, Shandong, China Applicant after: Disha Pharmaceutical Industry Group Corp., Ltd. Co-applicant after: Weihai Disu Pharmaceutical Co., Ltd. Co-applicant after: Disha Pharmaceutical Group Shandong Disha Pharmaceutical Co., Ltd. Address before: 264205 No. 1 South Qingdao Road, Weihai economic and Technological Development Zone, Shandong, China Applicant before: Disha Pharmaceutical Industry Group Corp., Ltd. Co-applicant before: Weihai Disu Pharmaceutical Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160831 Address after: 264205 No. 1 South Qingdao Road, Weihai economic and Technological Development Zone, Shandong, China Patentee after: Disha Pharmaceutical Industry Group Corp., Ltd. Patentee after: Weihai Disu Pharmaceutical Co., Ltd. Address before: 264205 No. 1 South Qingdao Road, Weihai economic and Technological Development Zone, Shandong, China Patentee before: Disha Pharmaceutical Industry Group Corp., Ltd. Patentee before: Weihai Disu Pharmaceutical Co., Ltd. Patentee before: Disha Pharmaceutical Group Shandong Disha Pharmaceutical Co., Ltd. |
|
DD01 | Delivery of document by public notice |
Addressee: Zou Yuanhua Document name: Notification of Passing Examination on Formalities |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130403 Termination date: 20200524 |
|
CF01 | Termination of patent right due to non-payment of annual fee |